AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06797102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Exercises
Description: Patients in this group received a neuromuscular training protocol along with general treatment for 10 minutes. This included hot packs, lumbar stretches, and ergonomic posture correction divided over 6 weeks The exercises performed included squatting, single leg stance, and balance reach leg and arm exercises with 10 repetitions each. They also did lunge exercises with five repetitions bilaterally, step up and down exercises with 10 repetitions, single leg standing on a balance mat with 10 repetitions and a 10-second hold, single board exercises, and single leg stance with weights and eyes closed for five minutes with a 10-second hold. Additionally, they stood on a wobble board with eyes closed five times with a 10-second hold. The protocol included running on a treadmill and trampoline for five minutes per day, running figure-of-eight patterns, and agility drills at a slow speed for five minutes each.
Study NCT06797102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Close Chain Exercises
Description: Patients in this group received closed chain exercises for core strengthening along with general treatment for 10 minutes, including hot packs, lumbar stretches, and ergonomic posture correction, divided over 6 weeks. The exercises included sets of squats, lunges, leg presses, wall squats, standing heel raises on a single leg, and single leg dead lifts. Each treatment session lasted 60 minutes, incorporating a warm-up and cool-down period of 10 minutes.
Study NCT06395636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infection-Prediction Algorithm
Description: This machine learning algorithm will be developed(Aim1a) and validated(Aim 1b) using the participant Fitbit data and survey results collected during Aim 1. In Aim 2 the algorithm will be used in real time to predict postoperative infection.
Study NCT05705765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension training
Description: Training with suspension devices. 12 sessions of 40-45 min in four weeks.
Study NCT06658964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1: JMKX003142 and itraconazole
Description: JMKX003142: Dose: 3 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg itraconazole once: Day8, once only in the morning.~Itraconazole：Dose: 200mg once；Day5-Day7 and Day9-Day11, QD
Study NCT06658964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2: JMKX003142 and rifampicin
Description: JMKX003142: Dose: 6 mg, D1, once only in the morning. 3 mg JMKX003142 coadministered with 200 mg rifampicin once: Day14, once only in the morning.~Rifampicin：Dose: 600mg once；Day5-Day13 and Day15-Day17, QD
Study NCT06661863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar ridge preservation with bioactive glass
Description: Bioactive glass grafted into alveolar preservation.
Study NCT06661863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar ridge preservation with autologous bone
Description: Autologous bone graft in alveolar ridge preservation.
Study NCT06658288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound Training
Description: 12 participants will be in experimental group A giving them rebound training.
Study NCT06658288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraband resistance exercise
Description: 12 participants will be in experimental group A giving them theraband resistance exercise with different band resistnce.
Study NCT06661707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonar guided Quadratus Lumborum block
Description: The probe will be tilted down the lateral abdomen to identify a bright hyperechoic line that represents the middle layer of the thoracolumbar fascia. The needle will be inserted in plane from anterolateral to posteromedial. The needle tip will be placed between the thoracolumbar fascia and the QL muscle, and after negative aspiration, the correct position of the needle will be proved by injection of 5 mL of normal saline to confirm the space with a hypoechoic image and hydrodissection. An injection of (0.2 mL/kg of 0.25% bupivacaine per side) will be applied without exceeding the toxic dose 3 mg/kg
Study NCT06661707 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sonar guided Ilioinguinal/Iliohypogastric block
Description: The ultrasound linear probe will be placed over the anterior superior iliac spine with the superior margin of the transducer pointed directly in an oblique plane toward the umbilicus. The iliohypogastric nerve will be seen medial to the ilioinguinal nerve. The overlying skin will be prepared with antiseptic solution and 21 gauge 120mm Locoplex Sono Tap cannula will be advanced using an in-plane approach from a point just below the inferior border of the transducer toward the ilioinguinal nerve as it lies within the facial plane between the internal abdominal oblique and transverse abdominis muscles.~After negative aspiration, (0.2 mL/kg of 0.25% bupivacaine per side) will be injected without exceeding the toxic dose of 3 mg/kg
Study NCT06659172 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study NCT06247631 — intervention group
Intervention type: OTHER
Intervention: STOP BANG
Description: The STOP-Bang Questionnaire is intended to give physicians an easy-to-use tool to identify people who might have obstructive sleep apnea (OSA). The questionnaire consists of eight yes-or-no questions based on the major risk factors for OSA. A STOP-Bang score of 2 or less is considered low risk, and a score of 5 or more is high risk for having either moderate or severe OSA. For people who score 3 or 4, doctors may need to perform further assessment to determine how likely they are to have OSA.
Study NCT06792656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized Forest Therapy session (120 min)
Description: standardized, 2-hrs Forest Therapy session following the INFTA Forest Therapy Guiding Sequence
Study NCT06795256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Percussion and position change in retrograde intrarenal surgery
Description: To evaluate the effectiveness of this homework on stone clearance rates after RIRC by giving instructions to the patient in the home environment and suggesting percussion (tapping) and movement/position changes to help spontaneous stone passage.
Study NCT06659172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: taVNS
Description: transauricular vagus nerve stimulation
Study NCT06662331 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Sagittal Split Osteotomy
Description: A surgical procedure to correct dentofacial deformities
Study NCT06660927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liac Bifurcation Stent Graft System
Description: to evaluate the Safety and Efficacy of the G-iliac Iliac Bifurcation Stent Graft System for Endovascular Repair of Common Iliac Artery Aneurysms(CIAA)
Study NCT06661317 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06658106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thera-Band Elastic Band-Assisted Progressive Resistance Training
Description: Thera-Band Elastic Band-Assisted Progressive Resistance Training: This intervention involves a structured exercise program using Thera-Band elastic bands for resistance training, conducted three times a week for 12 weeks. Each session lasts approximately 50 minutes and includes exercises targeting major muscle groups, such as upper arms, shoulders, chest, lumbar, and lower limbs. Participants will perform each exercise for 8-12 repetitions in 2-3 sets with 1-minute intervals, aiming for an intensity of 60%-80% of their maximum heart rate. The program is designed to improve strength, balance, and overall physical function, thereby reducing frailty in older adults with diabetes.
Study NCT06658106 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diabetes Management
Description: Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
Study NCT06658106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Diabetes Management
Description: Conventional Diabetes Management: Participants in this arm will receive standard care for diabetes management, which includes health education covering diet, medication adherence, exercise recommendations, and routine health monitoring. This arm serves as a comparator to assess the effectiveness of the progressive resistance training intervention.
Study NCT06661018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme Q 10
Description: participant will receive STEMI standard treatment plus oral Coenzyme Q10 (chewable tablet) 100 mg / 12 hours for 8 weeks
Study NCT06661018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participant will receive STEMI standard treatment plus placebo /12 hours for 8 weeks
Study NCT06608238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-MNA 200 mcg
Description: D-MNA , (doxorubicin) patch, 200 mcg
Study NCT06608238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-MNA 100 mcg
Description: D-MNA (doxorubicin) patch, 100 mcg
Study NCT06608238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: P-MNA patch, placebo
Study NCT06592014 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lithium aspartate
Description: Lithium aspartate with dosage adjusted to serum lithium level 0.25-0.50mmol/L
Study NCT06662136 — intervention group
Intervention type: BEHAVIORAL
Intervention: motivational interview
Description: Participants in the experimental group will be given motivational interviews about HPV at 4 different times and will also be given an educational brochure.
Study NCT06662136 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Participants in the control group will not receive any intervention.
Study NCT06659471 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% Sodium Monofluorophosphate Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study NCT06659471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study NCT06659471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% Stannous Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study NCT05625789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postural control (weight shift) training
Description: Visual cues to improve amplitude of weight shift prior to initiating gait.
Study NCT05625789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Steady state gait training
Description: Auditory cues are provided to increase amplitude of movement (e.g., step length) during continuous walking, to determine its effects on gait initiation amplitude of movement.
Study NCT06412978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: absorbable subcuticular polyglycolic acid staples (INSORB)
Description: Insorb absorbable staples are used for skin closure
Study NCT06412978 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subcuticular, polyglecaprone suture (Monocryl)
Description: Monocryl absorbable staples are used for skin closure
Study NCT06239220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1 t-haNK
Description: Allogeneic, stable, clonal natural killer cell line product, via intravenous infusion (into the vein) per protocol.
Study NCT06239220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
Study NCT06239220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human superagonist, via subcutaneous injection (under the skin) per protocol.
Study NCT05051293 — intervention group
Intervention type: OTHER
Intervention: serum concentration of estrogen (E1 and E2) and testosterone ratio measurement
Description: To measure the serum concentration of estrogen (E1 and E2) and testosterone ratio in all male cirrhosis patients
Study NCT06793293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High level laser
Description: It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) in addition to High level laser for 5 minutes on days 1 st , 2 nd , and 3 rd , after cesarean section (3 sessions)
Study NCT06793293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-steroidal anti- inflammatory drugs and antibiotics
Description: It will be consisted of twenty-five postoperative cesarean section women and will be treated by medical treatment (Non-steroidal anti- inflammatory drugs and antibiotics) only.
Study NCT06795828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotional support group
Description: Women who met the inclusion criteria and volunteered to participate in the study and were provided emotional support were administered the Personal Information Form, Visual Analog Scale, State Anxiety Inventory and Surgical Fear Scale via face-to-face interview method on the first day of their hospitalization before the caesarean section (pre-test). This application lasted 15-20 minutes. Enter a brief, descriptive title for this arm of the study.
Study NCT06506201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velys hip navigation
Description: Computer assisted surgery
Study NCT06506201 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: surgery without navigation
Study NCT04940351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GROUP - A: PIEZOCISION GROUP
Description: This group will receive piezocisions after placement of initial arch wire, in between the roots of mandibular anteriors (in a vertical line) i.e., between mandibular canine and lateral incisors bilaterally, lateral incisors and central incisors bilaterally and between two cental incisors with the help of piezotome. These piezocisions will be performed on the labial cortical bone only, 4mm below the interdental papilla under 2% lidocaine with 1:100,000 epinephrine and with standard asepsis, and gingival overlying will be incised first with blade number 15 in a Bard Parker handle. A piezosurgical microsaw with piezosurgical drill will be placed over that incision with irrigation. Then, vertical 5- to 8-mm and 3mm deep corticotomies will be perform using periapical radiographs as a guide to avoid penetrating into the adjacent roots. No subsequent sutures required.
Study NCT04940351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GROUP- B: MICRO-OSTEOPERFORATION GROUP
Description: This group will receive MOPs after initial arch wire placement. These MOPs will be performed under local anesthesia with standard asepsis, using a self drilling 1.6mm x 8mm orthodontic mini-implants and mini-implant screw driver and no flap will be raised. MOP's will be placed on five sites i.e., interproximally between mandibular canine and lateral incisors bilaterally, central incisor and lateral incisor bilaterally and between two central incisors. Each site will receive two MOP's, first 2mm apical to alveolar crest and second 2mm below the first in a vertical line and 2mm deep into the bone. Then the mini-implant will be removed by rotating the screw driver anticlockwise and pressure will be applied to achieve hemostasis.
Study NCT04882540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam
Description: * Pharmaceutical form: Film-coated tablets~* Concentration: 100 mg tablets~* Route of administration: Oral use
Study NCT06796751 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: DNA/RNA sequencing and bioinformatic data analysis
Description: DNA will be extracted from peripheral blood or from somatic tissues. In some cases (reported mosaicism on blood) a skin biopsy will be performed to obtain fibroblasts for further analysis (DNA/RNA extraction and preparation of cell culture for Hi-C).~LRS will be performed on extracted DNA using Oxford Nanopore Technology by two different approaches:~* Target, in samples with monoallelic alterations in genes related to autosomal recessive disease;~* Genomic in other cases. Sequencing data will be analyzed through a dedicated bioinformatics pipeline. LRS data analysis will include sequence alignment and variant quality checks, producing a per-sample quality report to ensure elimination of technical noise and to obtain a harmonized jointly-called dataset for downstream analyses. Mean depth of coverage, a general indicator of LRS sensitivity, will be achieved at 30X to guarantee 95% of callable genomic positions >20x.~To reconstruct the tridimensional structure of chromatin and the regions
Study NCT06793345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity intermittent walking training
Description: The intensity of the training is 60 to 80% of 6MWTdistance.
Study NCT06793098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of kisspeptin concentration
Description: Measurement of kisspeptin concentration in fasting venous blood serum
Study NCT06793098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of ghrelin concentration
Description: Measurement of ghrelin concentration in fasting venous blood serum
Study NCT06793098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of zonulin concentration
Description: Measurement of zonulin concentration in fasting venous blood serum
Study NCT06793930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A tailored, optimised, and person-centred critical pathway to promote sustainable lifestyle modification
Description: The TOP-S programme is a nurse-led intervention promoting the maintenance of lifestyle modification
Study NCT06793930 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Brief advice
Description: once-off brief lifestyle advice lasting for 15 minutes
Study NCT06795425 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postbiotic Active Lifestyle Blend
Description: The active intervention, Postbiotic Active Lifestyle Blend, containing a heat-treated blend of bacterial strains; 2 capsules per day.
Study NCT06795425 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention contains no active ingredients and consists of maltodextrin as an inactive ingredient. The capsule matches the appearance and dosage form of the active intervention.
Study NCT06792786 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA detection
Description: dynamically monitor the changes of ctDNA in patients with esophageal cancer Radiation: Radiotherapy 95% PTV50-50.4Gy/25-28fractions, 1.8-2Gy/1 fractions; 5 days a week; 6 weeks. Chemotherapy:weekly paclitaxel (50mg/m²) in combination with carboplatin (AUC=2) chemotherapy, a total of 4-5 cycles.~Other Names:~Intensity-modulated radiotherapy (IMRT) Drug: Toripalimab Toripalimab (240 mg, intravenously infused) will be administered as the maintenance treatment every 3 weeks within 4 weeks after the completion of radiotherapy for 1 years or until progression, intolerable toxicity, or physician/patient decision~Other Names:~Immunotherapy ctDNA detection: The first tissue and blood ctDNA test (T0) before treatment is based on next generation sequencing (NGS) technology, and ctDNA test is based on tumor- prior analysis informed assays method. Blood ctDNA testing after chemoradiotherapy was performed every 3 months
Study NCT06794060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (Ascorbic Acid)
Description: Participants swallow synthetic vitamin C tablets 500mg with water, twice a day.
Study NCT06794060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C (Ascorbic Acid)
Description: Participants swallow naturral vitamin C tablets 500mg with water, twice a day.
Study NCT06794060 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants swallow tablets with the same texture, flavor, and appearance as the experimental group 500mg with water, twice a day.
Study NCT06797544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 0.5%
Description: Intralesional levofloxacin (5 mg/ml, 100 ml, Tavanic®, Sanofi, France) will be injected into each lesion based on its size (5 mg/cm2). The infiltration of intralesional dose will be given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle will be used to infiltrate the lesion.~The lesion will be thoroughly infiltrated with the drug solution until the base will be completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously.
Study NCT06795074 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optilume
Description: Dilatation with drug-coated balloon
Study NCT06795074 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroMax Ultra
Description: Dilatation with non-coated balloon
Study NCT06437288 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy
Description: Receive an intravenous infusion of hematoporphyrin injection
Study NCT05308017 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Richard Wolf 24F Laser scope
Description: 24F Laser with HoLEP